Blood-Derived Products for Chronic Non-Healing Wounds — NCD 217 | CMS Coverage Update

CMS modified NCD 217 governing blood-derived products for chronic non-healing wounds, effective March 7, 2026. Here's what billing teams need to know about coverage criteria, exclusions, and MAC-determined indications.

The Centers for Medicare & Medicaid Services updated National Coverage Determination 217, which controls Medicare reimbursement for autologous platelet-rich plasma (PRP) and platelet-derived growth factor (PDGF) products used to treat chronic non-healing wounds. The core coverage rules trace back to April 13, 2021, but this 2026 modification refreshes the policy document and reaffirms what's covered, what's explicitly excluded, and — critically — where your local Medicare Administrative Contractor (MAC) holds the final say. No specific CPT or HCPCS codes are listed in this version of the policy data, which itself creates billing risk your team needs to account for.

Quick-Reference Table

CMS Blood-Derived Products Coverage Criteria and Medical Necessity Requirements 2026

The nationally covered indication under NCD 217 is narrow: autologous PRP for chronic non-healing diabetic wounds, for a duration of up to 20 weeks. That's the full extent of the nationally covered indications. The PRP must be prepared by a device with FDA clearance specifically for management of exuding cutaneous wounds, such as diabetic ulcers — a requirement your documentation needs to capture explicitly.

"Chronic non-healing" means the wound has persisted for 30 days or longer and has failed to progress through normal wound healing stages. That 30-day threshold isn't clinical background noise — it's a hard medical necessity criterion. If the wound hasn't crossed that 30-day mark, you don't have a covered indication under this NCD.

The distinction between autologous PRP and autologous PDGF matters enormously for billing. Autologous PRP contains whole cells — white cells, red cells, plasma, platelets, fibrin, stem cells, and fibrocyte precursors. Autologous PDGF does not contain cells. CMS draws a hard line between them: autologous PRP for diabetic wounds is covered; autologous PDGF for any chronic non-healing cutaneous wound is not covered nationally. Confusing the two in your documentation or charge capture is a straight path to a claim denial.

Homologous PRP — derived from multiple donors rather than the patient's own blood — is not addressed as a covered indication under the nationally covered section. Don't assume it's covered because it isn't explicitly excluded.

The prior authorization question under Medicare fee-for-service isn't answered by NCD 217 directly, but MAC-specific Local Coverage Determinations (LCDs) may impose documentation and prior auth requirements, especially for treatment beyond the 20-week nationally covered window. Know your MAC.

CMS Blood-Derived Products Exclusions and Non-Covered Indications

CMS is explicit about what NCD 217 does not cover nationally, and the list is consequential.

Autologous PDGF for chronic, non-healing cutaneous wounds is nationally non-covered. This includes products like Becaplermin's predecessors in the PDGF category. If you've been billing for autologous PDGF expecting Medicare reimbursement, those claims are at risk — and if they've been going through without denial, that's an audit exposure problem, not a billing success story.

Becaplermin — a non-autologous growth factor — is also nationally non-covered for chronic, non-healing subcutaneous wounds. Becaplermin may be familiar to wound care teams as a topical treatment option, but Medicare draws the line here clearly.

Autologous PRP applied directly to a closed incision for acute surgical wounds is non-covered. So is autologous PRP for dehiscent wounds. The covered indication requires a chronic wound (30+ days, non-healing). Surgical wound applications, even when PRP is technically the same product, fall outside the nationally covered box.

These aren't gray areas. They're hard exclusions. Document your wound etiology and duration meticulously, because the difference between a covered claim and a denied one often lives in the progress notes.

Coverage Indications at a Glance

CMS Blood-Derived Products Billing Guidelines and Action Items 2026

CPT, HCPCS, and ICD-10 Codes for Blood-Derived Products Under NCD 217

This version of NCD 217 does not list specific CPT, HCPCS Level II, or ICD-10-CM codes in the policy data. That's not an oversight on our part — the policy document itself does not enumerate codes.

This is a real billing problem. Claims for autologous PRP wound care services are typically submitted with HCPCS codes, but the specific codes applicable to your claims depend on the product, preparation method, and clinical setting — and your MAC's LCD almost certainly goes further than the NCD in specifying which codes it will accept.

What to do: Pull your MAC's applicable Local Coverage Determination and the associated Billing and Coding Article (formerly the LCD companion document). Those documents will list the specific HCPCS codes, any required modifiers, and the ICD-10-CM diagnosis codes your MAC considers covered. Build your charge capture from those documents, not from NCD 217 alone.

If your billing team or revenue cycle consultants haven't cross-referenced your wound care charge capture against the MAC's LCD and billing article in the last year, do that before submitting another PRP claim. The NCD sets the national floor; the MAC sets the operational billing rules.